Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Neonatal Perinatal Med ; 9(3): 233-42, 2016 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-27589549

RESUMEN

Necrotizing enterocolitis (NEC) is the most common acquired disease of the gastrointestinal tract (GIT) in premature infants and newborns. It is defined as an ulcerative inflammation of the intestinal wall. The clinical signs of incipient NEC are often very discrete, and range from localized intestinal symptoms to generalized signs of sepsis. NEC is classified depending on its severity into disease states according to the modified Bell's Classification. Treatment of NEC ranges, depending on its severity, from a conservative therapeutic approach to surgery with resection of the affected parts of the intestine. Mortality is considerably high in extremely small preterm infants reaching up to 42% of the affected children. Measures such as breastfeeding or alternatively nutrition with pasteurized human donor milk from a milk bank, administration of probiotics, avoidance of histamine type II receptor antagonists, and restrictive antibiotic treatment should be considered early on for prevention of NEC.


Asunto(s)
Enterocolitis Necrotizante , Enfermedades del Prematuro , Lactancia Materna , Enterocolitis Necrotizante/congénito , Enterocolitis Necrotizante/diagnóstico , Enterocolitis Necrotizante/prevención & control , Enterocolitis Necrotizante/terapia , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/diagnóstico , Enfermedades del Prematuro/epidemiología , Enfermedades del Prematuro/prevención & control , Enfermedades del Prematuro/terapia , Infusiones Parenterales/métodos , Lactoferrina/uso terapéutico , Probióticos/uso terapéutico , Factores de Riesgo , Sepsis/diagnóstico , Sepsis/epidemiología , Sepsis/prevención & control , Sepsis/terapia
2.
Klin Padiatr ; 223(7): 408-13, 2011 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-21969026

RESUMEN

The number of opiate addicted patients treated with opioid replacement therapy is continuously increasing. In Germany, 57.7% of these patients are treated with methadone and 18.6% with buprenorphine. This maintenance therapy provides several advantages while addicted pregnant women and their foetus have a high benefit from appropriate replacement therapy. However, the recommendations concerning breast feeding during an opioid replacement therapy are discussed controversially, because methadone as well as buprenorphine accumulate in breast milk. This accumulation might cause damages to the newborn's health; so, child benefits of breast feeding have to be balanced with possible health risks.This review provides an overview of a selective literature search based on the PubMed-database and german consensus recommendations. Used search terms included: (methadone*) AND (breastfeeding OR lactation), (methadone*) AND (human milk), (buprenorphine*) AND (breastfeeding OR lactation) and (buprenorphine*) AND (human milk).According to the available literature, addicted women, substinated with methadone or buprenorphine are allowed to breast feed their newborns. The advantages of breast feeding prevail the risks of an infant opiate intoxication caused by methadone or buprenorphine.


Asunto(s)
Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Lactancia Materna , Buprenorfina/administración & dosificación , Buprenorfina/efectos adversos , Metadona/administración & dosificación , Metadona/efectos adversos , Tratamiento de Sustitución de Opiáceos , Trastornos Relacionados con Opioides/rehabilitación , Analgésicos Opioides/farmacocinética , Lactancia Materna/efectos adversos , Buprenorfina/farmacocinética , Contraindicaciones , Relación Dosis-Respuesta a Droga , Femenino , Alemania , Humanos , Lactante , Recién Nacido , Masculino , Tasa de Depuración Metabólica , Metadona/farmacocinética , Leche Humana/metabolismo , Síndrome de Abstinencia Neonatal/etiología , Tratamiento de Sustitución de Opiáceos/efectos adversos , Embarazo
3.
Gesundheitswesen ; 71(8-9): 476-80, 2009 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-19431107

RESUMEN

AIM: The purpose of this study was to analyse metabolic control in patients with diabetes mellitus in primary care in Thuringia and to evaluate HbA1c mapping as a newly proposed method for population-based continuous monitoring of metabolic control in primary care. METHODS: A cross-sectional study (2nd quarter 2005) using the electronic data bases of Thuringian medical laboratories (HbA1c, postal code of GP) was undertaken. The study population comprised all Thuringian patients with diabetes mellitus who were treated in ambulatory care. A comparison was made between data from HbA1c mapping and data collected by GPs (general practitioner) of two selected areas. RESULTS: We collected 89,407 HbA1c tests by HbA1c mapping: the following values were obtained - mean HbA1c: 6.73+/-1.27%; HbA1c >/=7%: 32.6%; HbA1c >/=10%: 2.4% of all HbA1c tests. The mean HbA1c was 0.2% lower in HbA1c mapping compared to data collection in GPs (HbA1c 6.8+/-1.32% vs. 7.02+/-1.26%, p<0.001). The percentage of HbA1c tests below 7% was higher, HbA1c test results between 7% and 9% were less frequent in HbA1c mapping. Patient data were as follows: type 2 diabetes 98.7%, female gender: 57%, age 69.8+/-11.6 years, insulin therapy 28.8%. CONCLUSIONS: The Thuringian cross-sectional study 2005 showed acceptable results for metabolic control in ambulatory care. The results of HbA1c mapping were comparable to the data on glycaemic control of patients with diabetes mellitus in ambulatory care.


Asunto(s)
Diabetes Mellitus/diagnóstico , Diabetes Mellitus/terapia , Hemoglobina Glucada/análisis , Tamizaje Masivo/métodos , Atención Primaria de Salud/métodos , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Diabetes Mellitus/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto Joven
4.
Br J Dermatol ; 156(5): 1020-6, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17388925

RESUMEN

BACKGROUND: The topical calcineurin inhibitors pimecrolimus and tacrolimus have been demonstrated to be an effective new anti-inflammatory therapy. The only clinically relevant side-effect reported is transient application site burning and stinging itch at the beginning of topical therapy. OBJECTIVES: In order to understand the underlying mechanism of this effect, we examined whether or not the compounds are able to stimulate neuropeptide release in normal murine skin as well as in a mouse model of experimentally induced irritant contact dermatitis. METHODS: Balb/c mice were treated with 1% pimecrolimus cream or 0.1% tacrolimus ointment. Untreated and corresponding vehicle-treated mice served as controls. Skin specimens were investigated by light, immunofluorescence and electron microscopy as well as enzyme-linked immunosorbent assay and polymerase chain reaction. RESULTS: Topical application of pimecrolimus and tacrolimus was followed by an initial release of substance P and calcitonin gene-related peptide from primary afferent nerve fibres in murine skin during the early inflammatory response. The release of the neuropeptides and their binding to mast cells (MCs) led to MC degranulation. Mediators of MCs such as histamine and tryptase may induce pruritus and burning by binding to the corresponding receptors (histamine receptor 1, proteinase-activated receptor 2) on sensory nerve fibres, which explains the initial side-effects during therapy with calcineurin inhibitors. CONCLUSIONS: It may be speculated that calcineurin inhibitors directly stimulate intracellular signalling pathways or bind to ion channels such as transient receptor potential vanilloid 1 or receptors involved in nociception.


Asunto(s)
Degranulación de la Célula , Inmunosupresores/farmacología , Mastocitos/efectos de los fármacos , Neuropéptidos/efectos de los fármacos , Tacrolimus/análogos & derivados , Tacrolimus/farmacología , Administración Tópica , Animales , Dermatitis por Contacto/tratamiento farmacológico , Mastocitos/fisiología , Ratones , Ratones Endogámicos BALB C , Modelos Animales , Neuropéptidos/metabolismo , Pomadas , Piel/efectos de los fármacos , Sustancia P/metabolismo
5.
Hautarzt ; 55(9): 855-68, 2004 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-15340711

RESUMEN

From the clinician's point of view, pruritus in children is quite frequent. It mainly occurs along with dermatoses but rarely with systemic diseases such as renal and liver failure or with genetic disorders. Mostly, it appears in the setting of atopic dermatitis (AD). Other frequent differential diagnoses comprise e.g. scabies, impetigo, varicella, tinea, urticaria, mastocytosis and psoriasis. In children, pruritus is most often associated with severe scratching leading to artefacts. This group of patients requires a therapeutical regimen of its own. The use of topical and systemic treatments depends on the underlying aetiology of pruritus and the stage and status of the skin. The physician has to consider that topically applied drugs may cause intoxication due to the different body volume/body surface proportion, especially in newborns and infants. The dosages of systemic drugs need to be adapted in children and UV phototherapy should be performed with caution due to possible longterm photo damage of the skin. Physicians feel more insecurity treating pruritus in children, especially when systemic treatments are taken into consideration. We want to highlight the major aetiologies of pruritus in children and point out the cornerstones of antipruritic therapy in this challenging group of patients in recognition of our own clinical experiences and the current literature.


Asunto(s)
Antipruriginosos/administración & dosificación , Dermatitis/diagnóstico , Dermatitis/tratamiento farmacológico , Prurito/diagnóstico , Prurito/tratamiento farmacológico , Adolescente , Antipruriginosos/clasificación , Niño , Preescolar , Dermatitis/clasificación , Dermatitis/complicaciones , Diagnóstico Diferencial , Femenino , Guías como Asunto , Humanos , Lactante , Recién Nacido , Masculino , Fotoquimioterapia , Pautas de la Práctica en Medicina , Prurito/clasificación , Prurito/etiología , Resultado del Tratamiento
6.
Clin Nephrol ; 59(6): 429-35, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12834174

RESUMEN

BACKGROUND: Parathyroid hormone (PTH) has specific effects on function, migration and proliferation of human leukocytes. These effects may contribute to accelerated atherosclerosis and impaired immune response observed in patients with renal insufficiency. Recently, a new G protein-coupled receptor with substantial implications for vascular function--the PTH2 receptor (PTH2-R)--has been identified, however, expression and distribution in humans and a possible regulation has not yet been studied. We therefore investigated the expression of the PTH2 receptor on human leukocytes in healthy subjects and in patients with hyperparathyroidism. METHODS: PTH2 receptor expression was quantified by flow cytometry (FACS) analysis on monocytes, lymphocytes and granulocytes that were isolated from peripheral blood (hypotonic density gradient centrifugation) and by immunohistochemistry using a specific alpha-PTH2-R antibody produced in rabbit. Results of 22 patients with hyperparathyroidism (12 renal allograft recipients, 10 hemodialysis patients, mean age 43 +/- 8 years) were compared to 22 age and sex-matched healthy controls. RESULTS: Mean relative antigen density of the PTH2 receptor and percentage of positive cells in healthy subjects was 19 +/- 5 and 90 +/- 6% on granulocytes, 5 +/- 2 and 55 +/- 19% on monocytes, and 24 +/- 7 and 21 +/- 7% on lymphocytes. In patients with hyperparathyroidism, mean antigen density was significantly lower on granulocytes and monocytes (17 +/- 4% and 3 +/- 1%, p < 0.01, respectively). The percentage of positive cells and mean expression on lymphocytes was not significantly different. A significant and inverse correlation was found between plasma PTH concentrations and the mean PTH2 receptor expression on granulocytes (r = -0.41, p < 0.05). CONCLUSIONS: The PTH2 receptor is expressed on human granulocytes and--to a lesser degree--on monocytes and lymphocytes. In patients with hyperparathyroidism the PTH2 receptor is down-regulated as function of plasma PTH levels.


Asunto(s)
Hiperparatiroidismo/metabolismo , Leucocitos/metabolismo , Receptores de Hormona Paratiroidea/metabolismo , Adulto , Animales , Estudios de Casos y Controles , Regulación hacia Abajo , Femenino , Citometría de Flujo , Humanos , Inmunohistoquímica , Masculino , Conejos , Receptor de Hormona Paratiroídea Tipo 2
7.
Thorax ; 58(7): 613-7, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12832680

RESUMEN

BACKGROUND: Chronic airway inflammation and recurrent infections are a core phenomenon in cystic fibrosis (CF). Diagnosing acute infectious exacerbations is difficult in the presence of chronic inflammatory processes. S100A12 exhibits proinflammatory functions via interaction with the multiligand receptor for advanced glycation end products. Blocking this interaction inhibits inflammatory processes in mice. METHODS: The expression of S100A12 in lung specimens of patients with end stage lung disease of CF was investigated, and S100A12 levels in the serum of patients with acute infectious exacerbations of CF were measured. RESULTS: Immunohistochemical studies of CF lung biopsy specimens revealed a significant expression of S100A12 by infiltrating neutrophils. High S100A12 levels were found in the sputum of patients with CF, and serum levels of S100A12 during acute infectious exacerbations were significantly increased compared with healthy controls (median 225 ng/ml v 46 ng/ml). After treatment with intravenous antibiotics the mean S100A12 level decreased significantly. There was also a significant difference between S100A12 levels in patients with acute infectious exacerbations and 18 outpatients without exacerbations (median 225 ng/ml v 105 ng/ml). CONCLUSIONS: S100A12 is extensively expressed at local sites of inflammation in CF. It is a serum marker for acute infectious exacerbations. High local expression of S100A12 suggests that this protein has a proinflammatory role during airway inflammation and may serve as a novel target for anti-inflammatory treatments.


Asunto(s)
Infecciones Bacterianas/complicaciones , Fibrosis Quística/metabolismo , Proteínas S100/metabolismo , Adolescente , Adulto , Bronquitis/metabolismo , Proteína C-Reactiva/metabolismo , Niño , Preescolar , Fibrosis Quística/complicaciones , Ensayo de Inmunoadsorción Enzimática , Humanos , Inmunohistoquímica/métodos , Lactante , Proteína S100A12 , Esputo/metabolismo , Estadísticas no Paramétricas
8.
Exp Dermatol ; 10(6): 391-404, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11737258

RESUMEN

To investigate the pathomechanisms of leukocytoclastic vasculitis (LcV) we compared mouse models of LcV with non-vasculitic irritant contact dermatitis (ICD). Criteria for LcV as met by the immune complex-mediated Arthus reaction (Art-r) were also fulfilled by the localized Shwartzman reaction (Shw-r) and by cutaneous Loxoscelism (Lox) (injection of venom from Loxosceles reclusa containing sphingomyelinase D). After depletion of PMN (by gamma-irradiation) vessel damage could not be elicited in these models, distinguishing them from models of direct endothelial insult (necrotizing ICD). Depletion of complement could only delay, but not inhibit the Art-r, and did not change ICD, Lox or the Shw-r. The Shw-r exclusively revealed a sustained local expression of vascular adhesion molecules for 24 h in the preparatory phase (LPS s.c.), not observed in the Art-r, in Lox or ICD. Subsequent challenge with LPS i.p. was associated with upregulation of Mac-1 and ICAM-1 on PMN, but not of VLA-4 or LFA-1 (FACS analysis). Cytokines which were able to replace LPS in priming for LcV in the Shw-r (TNF-alpha and IL-1beta) also induced sustained expression of adhesion molecules, whereas IL-12 and IFN-gamma did neither. Neutralizing IL-12 or IFN-gamma also inhibited neither LcV nor sustained expression of adhesion molecules, whereas anti-TNF-alpha inhibited both. Anti-TNF-alpha had no marked inhibitory effects in the Art-r, in Lox or ICD. Combined (but not separate) neutralization of both E-selectin and VCAM-1 by antibodies suppressed LcV independent from reducing influx of PMN, proving that their sustained expression is decisive for the Shw-r and interferes with normal diapedesis. Since Loxosceles venom is known to dysregulate diapedesis and degranulation of PMN in vitro, since adherent immune complexes activate PMN at the vessel wall, and since adhesion molecules are dysregulated in the Shw-r, we suggest that LcV develops when activation of PMN coincides with vascular alterations which interfere with normal diapedesis.


Asunto(s)
Leucocitos/patología , Piel/irrigación sanguínea , Vasculitis/etiología , Vasculitis/patología , Animales , Reacción de Arthus/patología , Células Sanguíneas/metabolismo , Vasos Sanguíneos/patología , Activación de Complemento/fisiología , Citocinas/fisiología , Dermatitis por Contacto/patología , Selectina E/fisiología , Extravasación de Materiales Terapéuticos y Diagnósticos/etiología , Hemorragia/patología , Molécula 1 de Adhesión Intercelular/metabolismo , Leucaféresis , Antígeno de Macrófago-1/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Fenómeno de Shwartzman/patología , Piel/efectos de los fármacos , Piel/patología , Enfermedades de la Piel/patología , Venenos de Araña/farmacología , Molécula 1 de Adhesión Celular Vascular/fisiología , Vasculitis/complicaciones
9.
Eur J Pediatr ; 160(8): 492-6, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11548187

RESUMEN

UNLABELLED: We report the clinical course of a 6.5-year-old boy with refractory auto-immune haemolytic anaemia. Due to failure of conventional immunosuppressive therapy, an autologous peripheral blood stem cell transplantation was performed. The conditioning regimen consisted of cyclophosphamide and anti-thymocyte globulin. The patient was reinfused with 2.6 x 10(6) CD34 positive selected, B- and T-cell-depleted peripheral blood stem cells per kg body weight. He showed a partial response with a reduced demand for red blood cell transfusions. However, due to persistence of the haemolytic process he was started on rituximab therapy on day +40 post-transplant. Following two doses of rituximab, the patient improved rapidly and developed a sustained complete response. After 10 months, haemolysis recurred and responded again to rituximab therapy without the necessity for red blood cell transfusions. 15 months after initial antibody treatment, however, the patient developed a second relapse which was now refractory to rituximab therapy although CD20+ B-lymphocytes were cleared from the peripheral blood. CONCLUSION: Our case report suggests that rituximab and autologous peripheral blood stem cell transplantation are important though not curative elements in the treatment of patients with severe auto-immune haemolytic anaemia who are refractory to conventional immunosuppressive therapy.


Asunto(s)
Anemia Hemolítica Autoinmune/terapia , Anemia Refractaria/terapia , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas , Anemia Hemolítica Autoinmune/sangre , Anemia Hemolítica Autoinmune/tratamiento farmacológico , Anemia Refractaria/tratamiento farmacológico , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20/sangre , Niño , Humanos , Masculino , Recurrencia , Rituximab
10.
Syst Appl Microbiol ; 21(3): 340-5, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9841124

RESUMEN

Malonomonas rubra is a microaerotolerant fermenting bacterium which can maintain its energy metabolism for growth by decarboxylation of malonate to acetate. 16S rRNA sequence analysis revealed that M. rubra is closely related to the cluster of mesophilic sulfur-reducing bacteria within the delta subclass of the Proteobacteria, with the fermenting bacterium Pelobacter acidigallici and the sulfur reducers Desulfuromusa kysingii, D. bakii and D. succinoxidans as closest relatives. The cells contain high amounts (up to 12% of the total cell protein content) of a c-type cytochrome which is present mainly (> 60%) in the cytoplasm and to minor parts in the periplasm (> 20%) and associated with the membrane fraction (> 10%), independent of the growth substrate. This cytochrome is a tetraheme cytochrome of 13,700 Da molecular mass with a midpoint redox potential of -0.210 V.M. rubra does not reduce sulfur or ferric iron compounds. Since this cytochrome appears not to be involved in the energy metabolism it is concluded that it is a remnant of sulfur-reducing ancestors of this bacterium, without a conceivable physiological function in its present energy metabolism.


Asunto(s)
Grupo Citocromo c/metabolismo , Bacterias Anaerobias Gramnegativas/genética , Bacterias Anaerobias Gramnegativas/metabolismo , Bacterias Reductoras del Azufre/metabolismo , Grupo Citocromo c/química , Grupo Citocromo c/aislamiento & purificación , ADN Bacteriano/genética , ADN Ribosómico/genética , Fermentación , Genes Bacterianos , Bacterias Anaerobias Gramnegativas/clasificación , Malonatos/metabolismo , Datos de Secuencia Molecular , Oxidación-Reducción , Filogenia , ARN Ribosómico 16S/genética , Análisis de Secuencia de ADN , Azufre/metabolismo , Bacterias Reductoras del Azufre/clasificación , Bacterias Reductoras del Azufre/genética
11.
J Bacteriol ; 180(14): 3686-91, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9658015

RESUMEN

An extracellular electron carrier excreted into the growth medium by cells of Geobacter sulfurreducens was identified as a c-type cytochrome. The cytochrome was found to be distributed in about equal amounts in the membrane fraction, the periplasmic space, and the surrounding medium during all phases of growth with acetate plus fumarate. It was isolated from periplasmic preparations and purified to homogeneity by cation-exchange chromatography, gel filtration, and hydrophobic interaction chromatography. The electrophoretically homogeneous cytochrome had a molecular mass of 9.57 +/- 0.02 kDa and exhibited in its reduced state absorption maxima at wavelengths of 552, 522, and 419 nm. The midpoint redox potential determined by redox titration was -0.167 V. With respect to molecular mass, redox properties, and molecular features, this cytochrome exhibited its highest similarity to the cytochromes c of Desulfovibrio salexigens and Desulfuromonas acetoxidans. The G. sulfurreducens cytochrome c reduced ferrihydrite (Fe(OH)3), Fe(III) nitrilotriacetic acid, Fe(III) citrate, and manganese dioxide at high rates. Elemental sulfur, anthraquinone disulfonate, and humic acids were reduced more slowly. G. sulfurreducens reduced the cytochrome with acetate as an electron donor and oxidized it with fumarate. Wolinella succinogenes was able to reduce externally provided cytochrome c of G. sulfurreducens with molecular hydrogen or formate as an electron donor and oxidized it with fumarate or nitrate as an electron acceptor. A coculture could be established in which G. sulfurreducens reduced the cytochrome with acetate, and the reduced cytochrome was reoxidized by W. succinogenes in the presence of nitrate. We conclude that this cytochrome can act as iron(III) reductase for electron transfer to insoluble iron hydroxides or to sulfur, manganese dioxide, or other oxidized compounds, and it can transfer electrons to partner bacteria.


Asunto(s)
Grupo Citocromo c/metabolismo , FMN Reductasa , Bacterias Anaerobias Gramnegativas/enzimología , NADH NADPH Oxidorreductasas/metabolismo , Transporte de Electrón , Bacterias Anaerobias Gramnegativas/metabolismo , Periplasma/metabolismo
13.
Antonie Van Leeuwenhoek ; 70(1): 11-20, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8836437

RESUMEN

An anaerobic bacterium was isolated from a polluted sediment, with succinate and yeast extract as carbon and energy sources. The new strain was Gram-positive, the cells were coccal shaped, the mol% G+G content of the genomic DNA was 29, and the peptidoglycan was of the L-ornithine-D-glutamic acid type. Comparative sequence analysis of the 16S rRNA gene showed the new strain to belong to the genus Peptostreptococcus. Succinate, fumarate, pyruvate, 3-hydroxybutyrate and lysine supported growth. Succinate was degraded to propionate and presumably CO2, with a stoichiometric cell yield. Key enzymes of the methylmalonyl-CoA decarboxylase pathway were present. The methylmalonyl-CoA decarboxylase activity was avidin-sensitive and sodium dependent, and about 5 mM Na+ was required for maximal activity. Whole cells, however, required at least 50 mM sodium for maximal succinate decarboxylation activity and to support the maximum growth rate. Sodium-dependent energy conservation coupled to succinate decarboxylation is shown for the first time to occur in a bacterium belonging to the group of Gram-positive bacteria containing the peptostreptococci and their relatives.


Asunto(s)
Sodio/farmacología , Succinatos/metabolismo , Bacterias Anaerobias/metabolismo , Carboxiliasas , División Celular , Clasificación , Descarboxilación , Bacterias Grampositivas/metabolismo , Metilmalonil-CoA Descarboxilasa , Microscopía Electrónica , Microscopía de Contraste de Fase , Datos de Secuencia Molecular , Filogenia , Propionatos/metabolismo , ARN Ribosómico 16S/genética , Ácido Succínico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA